6,6-Dimethyl-3-propylthio-1-(pyrazol-3-yl)-4,5,6,7-tetrahydrobenzo[c]thiophen-4-one

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 6,6-Dimethyl-3-propylthio-1-(pyrazol-3-yl)-4,5,6,7-tetrahydrobenzo[c]thiophen-4-one
• 英文别名: 6,6-dimethyl-3-(propylsulfanyl)-1-(1H-pyrazol-3-yl)-6,7-dihydro-2-benzothiophen-4(5H)-one；6,6-Dimethyl-3-propylsulfanyl-1-(1H-pyrazol-3-yl)-6,7-dihydro-5H-benzo[c]thiophen-4-one；6,6-dimethyl-3-propylsulfanyl-1-(1H-pyrazol-5-yl)-5,7-dihydro-2-benzothiophen-4-one
• 化学式: C₁₆H₂₀N₂OS₂
• 分子量: 320.48
• InChiKey: RBWPBJRIJOEHCN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  99.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-乙酰基-6,6-二甲基-3-甲基硫代-4,5,6,7-四氢苯并[C]噻吩-4-酮 在 sodium hydride 、 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 6,6-Dimethyl-3-propylthio-1-(pyrazol-3-yl)-4,5,6,7-tetrahydrobenzo[c]thiophen-4-one
  参考文献：
  名称：

  高效，选择性和口服可生物利用的富含亮氨酸的重复激酶2（LRRK2）抑制剂

  摘要：

  最近，家族性帕金森氏病病例与富含亮氨酸的重复激酶2（LRRK2）基因有关。已经假设LRRK2蛋白的抑制可能具有改变疾病发病机理的潜力。从内部默克样品收集的高通量筛选中鉴定出了有效的，选择性的，口服生物利用的LRRK2抑制剂的二氢苯并噻吩系列。最初围绕核心进行的SAR研究将该系列确立为可治疗帕金森氏病的LRRK2抑制剂的易处理小分子先导系列。还发现将内酰胺掺入核心中大大改善了这些小分子的CNS和DMPK特性。

  DOI：

  10.1016/j.bmcl.2016.04.021

文献信息

• [EN] COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY<br/>[FR] COMPOSÉS INHIBANT L'ACTIVITÉ ENZYMATIQUE DE LA KINASE À MOTIFS RÉPÉTÉS RICHES EN LEUCINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2012118679A1

  公开（公告）日：2012-09-07

  Disclosed are compounds of Formula I: and the pharmaceutically acceptable salts thereof, wherein "A" is S-; -SO-, -SO2-, -O- or NRa-, and Ra, and R1 through R5 are defined herein. Also disclosed are pharmaceutical formulations comprising a compound of Formula I and methods of treating, managing, or ameliorating diseases amenable to treatment, management, or amelioration by inhibition of LRRK2 kinase activity, for example, Parkinson's disease.

  本文披露了Formula I的化合物及其药用盐，其中“A”为S-；-SO-；-SO2-；-O-或NRa-，而Ra和R1至R5在此定义。还披露了包括Formula I化合物的药物配方，以及通过抑制LRRK2激酶活性来治疗、管理或改善可通过此方式治疗、管理或改善的疾病的方法，例如帕金森病。
• COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY
  申请人：McCauley John A.

  公开号：US20130338106A1

  公开（公告）日：2013-12-19

  Disclosed are compounds of Formula I: and the pharmaceutically acceptable salts thereof, wherein “A” is S—; —SO—, —SO 2 —, —O— or NR a- , and R a , and R 1 through R 5 are defined herein. Also disclosed are pharmaceutical formulations comprising a compound of Formula I and methods of treating, managing, or ameliorating diseases amenable to treatment, management, or amelioration by inhibition of LRRK2 kinase activity, for example, Parkinson's disease.

  本发明涉及公式I的化合物及其药学上可接受的盐，其中“A”为S—；—SO—、—SO2—、—O或NRa-，Ra和R1至R5在此定义。本发明还涉及包含公式I化合物的制药配方以及通过抑制LRRK2激酶活性进行治疗、管理或改善可治疗、管理或改善的疾病的方法，例如帕金森病。
• Identification of a Novel, Selective GABA_A α5 Receptor Inverse Agonist Which Enhances Cognition
  作者：Mark S. Chambers、John R. Atack、Howard B. Broughton、Neil Collinson、Susan Cook、Gerard R. Dawson、Sarah C. Hobbs、George Marshall、Karen A. Maubach、Goplan V. Pillai、Austin J. Reeve、Angus M. MacLeod

  DOI：10.1021/jm020582q

  日期：2003.5.1

  In pursuit of a GABA(A) alpha5-subtype-selective inverse agonist to enhance cognition, a series of 6,7-dihydro-2-benzothiophen-4(5H)-ones has been identified as a novel class of GABAA receptor ligands. These thiophenes have higher binding affinity for the GABA(A) alpha(5) receptor subtype compared to the GABA(A) alpha(1), alpha(2), and alpha(3) subtypes, and several analogues exhibit high GABA(A) (alpha(5) receptor inverse agonism. 6,6-Dimethyl-3-(2-hydroxyethyl)thio-1-(thiazol-2-yl)-6,7-dihydro2-benzothiophen-4(5H)-one (43) has been identified as a full inverse agonist at the GABA(A) alpha5 receptor and is functionally selective over the other major GABA(A) receptor subtypes. 43 readily penetrates into the CNS to give selective occupancy of GABA(A) alpha5 receptors. In addition, 43 enhances cognitive performance in rats in the delayed 'matching-to-place' Morris water maze test-a hippocampal-dependent memory task-without the convulsant or proconvulsant activity associated with nonselective, GABA(A) receptor inverse agonists.
• THIENYLCYCLOHEXANONE DERIVATIVES AS LIGANDS OF THE GABA A alpha5 RECEPTOR SUBTYPE
  申请人：MERCK SHARP & DOHME LTD.

  公开号：EP0937072B1

  公开（公告）日：2002-01-09
• US6262103B1
  申请人：——

  公开号：US6262103B1

  公开（公告）日：2001-07-17